Myelodysplastic syndrome
RecruitingStudy on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA
Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA
- Disease:Myelodysplastic syndrome
- Substances:Epoetin AlfaLuspatercept
France- Participants:18–64 years · 65+ years
- Substances:Epoetin Alfa
- Sponsor:Groupe Francophone Des Myelodysplasies











